Literature DB >> 23690094

Summarizing the incidence of adverse events using volcano plots and time intervals.

Richard C Zink1, Russell D Wolfinger, Geoffrey Mann.   

Abstract

BACKGROUND: Adverse event incidence analyses are a critical component for describing the safety profile of any new intervention. The results typically are presented in lengthy summary tables. For therapeutic areas where patients have frequent adverse events, analysis and interpretation are made more difficult by the sheer number and variety of events that occur. Understanding the risk in these instances becomes even more crucial.
PURPOSE: We describe a space-saving graphical summary that overcomes the limitations of traditional presentations of adverse events and improves interpretability of the safety profile.
METHODS: We present incidence analyses of adverse events graphically using volcano plots to highlight treatment differences. Data from a clinical trial of patients experiencing an aneurysmal subarachnoid hemorrhage are used for illustration. Adjustments for multiplicity are illustrated.
RESULTS: Color is used to indicate the treatment with higher incidence; bubble size represents the total number of events that occur in the treatment arms combined. Adjustments for multiple comparisons are displayed in a manner to indicate clearly those events for which the difference between treatment arms is statistically significant. Furthermore, adverse events can be displayed by time intervals, with multiple volcano plots or animation to appreciate changes in adverse event risk over time. Such presentations can emphasize early differences across treatments that may resolve later or highlight events for which treatment differences may become more substantial with longer follow-up. LIMITATIONS: Treatment arms are compared in a pairwise fashion.
CONCLUSIONS: Volcano plots are space-saving tools that emphasize important differences between the adverse event profiles of two treatment arms. They can incorporate multiplicity adjustments in a manner that is straightforward to interpret and, by using time intervals, can illustrate how adverse event risk changes over the course of a clinical trial.

Entities:  

Mesh:

Year:  2013        PMID: 23690094     DOI: 10.1177/1740774513485311

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  7 in total

Review 1.  Statistical challenges for central monitoring in clinical trials: a review.

Authors:  Koji Oba
Journal:  Int J Clin Oncol       Date:  2015-10-23       Impact factor: 3.402

2.  Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).

Authors:  Denong Wang; Roopa Bhat; Raymond A Sobel; Wei Huang; Lai-Xi Wang; Tomas Olsson; Lawrence Steinman
Journal:  Drug Dev Res       Date:  2014-03-11       Impact factor: 4.360

Review 3.  Analysis and reporting of adverse events in randomised controlled trials: a review.

Authors:  Rachel Phillips; Lorna Hazell; Odile Sauzet; Victoria Cornelius
Journal:  BMJ Open       Date:  2019-03-01       Impact factor: 2.692

Review 4.  Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy.

Authors:  Rachel Phillips; Odile Sauzet; Victoria Cornelius
Journal:  BMC Med Res Methodol       Date:  2020-11-30       Impact factor: 4.615

5.  A multicentre, randomized, parallel group, superiority study to compare the clinical effectiveness and cost-effectiveness of external frame versus internal locking plate for complete articular pilon fracture fixation in adults.

Authors:  Lydia Flett; Joy Adamson; Elizabeth Barron; Stephen Brealey; Belen Corbacho; Matthew L Costa; Graham Gedney; Nikolaos Giotakis; Catherine Hewitt; Jessica Hugill-Jones; Deborah Hukins; Ada Keding; Catriona McDaid; Alex Mitchell; Matthew Northgraves; Grace O'Carroll; Adwoa Parker; Arabella Scantlebury; Lynne Stobbart; David Torgerson; Emma Turner; Charlie Welch; Hemant Sharma
Journal:  Bone Jt Open       Date:  2021-03

6.  Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials.

Authors:  Victoria Cornelius; Suzie Cro; Rachel Phillips
Journal:  Trials       Date:  2020-12-22       Impact factor: 2.279

7.  A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial.

Authors:  Suzie Cro; Prakash Patel; Jonathan Barker; David A Burden; Christopher E M Griffiths; Helen J Lachmann; Nick J Reynolds; Richard B Warren; Francesca Capon; Catherine Smith; Victoria Cornelius
Journal:  Trials       Date:  2020-02-10       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.